• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Moderna’s Wider 2026 Loss Amid Pipeline Spend Change The Bull Case For MRNA?

    Simply Wall St·08/03/2026 03:30:04
    Listen to the news
    • In the past quarter, Moderna, Inc. reported second-quarter 2026 revenue of US$145 million versus US$142 million a year earlier, with a net loss of US$782 million and basic loss per share from continuing operations of US$1.97, while also updating investors on its norovirus and influenza vaccine programs.
    • Across the first half of 2026, revenue rose to US$534 million from US$250 million, but the net loss widened to US$2.13 billion and basic loss per share from continuing operations increased to US$5.36, underscoring the cost of advancing its expanding mRNA pipeline.
    • Next, we’ll examine how Moderna’s wider first-half loss and ongoing vaccine development efforts may influence its existing investment narrative.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

    Moderna Investment Narrative Recap

    To own Moderna today, you need to believe its mRNA platform can move beyond a volatile COVID franchise into a broader, commercially viable vaccine and therapeutics portfolio. The latest update, including a slightly narrower Q2 loss and mixed trial news, does not appear to materially change the near term focus on the FDA decision for its influenza vaccine mFLUSIVA, while the biggest current risk remains ongoing heavy losses to fund pipeline development.

    The most relevant update here is the pending FDA decision on mFLUSIVA, following a unanimous advisory committee recommendation for adults 50 and older. This filing sits at the center of Moderna’s push to build a seasonal respiratory portfolio, and the Q2 results underscore how dependent the story still is on timely approvals and uptake of new vaccines to offset ongoing R&D spend and a widening year to date loss.

    But investors should also be aware that the real concern is how long Moderna can absorb multi billion dollar annual losses if key vaccines face delays or weaker uptake...

    Read the full narrative on Moderna (it's free!)

    Moderna's narrative projects $3.7 billion revenue and $695.7 million earnings by 2029.

    Uncover how Moderna's forecasts yield a $44.25 fair value, a 19% downside to its current price.

    Exploring Other Perspectives

    MRNA 1-Year Stock Price Chart
    MRNA 1-Year Stock Price Chart

    Some of the lowest ranked analysts were already projecting only about 3.5 percent annual revenue growth and ongoing losses, so compared with the consensus catalyst around flu approval, they frame a much more pessimistic picture of Moderna’s risk and reward that this latest earnings and pipeline update could either reinforce or challenge.

    Explore 6 other fair value estimates on Moderna - why the stock might be worth less than half the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
    • Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

    Curious About Other Options?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.